click enter text
initi peer perform pt consensu look fair
invest view long-term benefit pki capit deploy new
growth initi vanadi euroimmun genet wide appreci
price-to-earnings vs peer bp higher year ago flag earli
organ acceler like estim within
consensu consensu model bp organ acceler
upsid like bottom line expect histor
percept structur lower margin busi vs tool fade
new product drop-through drive acceler margin expans
downsid pki higher exposur vs trade dynam polici
risk china concern vanadi initi clinic
commerci proven point risk fairli balanc rate
break consensu consensu estim bp
acceler assum either base busi deterior new product
initi miss target altern view consensu may model
reason buffer account polici uncertainti admittedli risk
slightli consensu estim deconstruct true organ
margin howev flag consensu assum least margin
degrad organ next year set bar low ep all-in ep
upsid look like
valuat framework pt deriv forecast
target yield yield target tool group averag
account pki faster growth profil detail valuat methodolog
accompani industri report target yield explicitli
reflect macro trend risk identifi pki-specif macro correl
seri forecast assum increment free cash deploy
return
trade fundament data
upsid target
price
report limit sole use client wolf research pleas refer disclosur section locat end
report analyst certif import disclosur disclosur
page
consensu near-term cautiou
fear elev low china visibl
stock react neg below-
expect elev fear regard
impact china tariff understand
pki exposur china meaning
sale play categori
local european substitut
readili avail high spec
detect equip bigger focu
certain chemistri key line
deserv credit smart sharp
reorient portfolio toward diagnost
categori trim select busi
own stock advanc clariti
impact elev tariff strike us unwis
tariff resolut clariti ground level
detail china custom respond
elev conflict would posit
given attract increment growth ahead
new diagnost offer
gain traction life scienc
survey analysi highlight new posit
trend lab survey intend
primarili address trend market share
waters/thermofisher/agil share dynam
pharma academ lab space
histor effort survey environ found meaning share trend unsurpris
given compani limit concentr mass spec/lc pure life scienc vertic rel
appli food/environmental/clin market first time experi pick share trend
meaning posit suggest da initi gain traction core life scienc
exhibit gain share pharma lab servic softwar exhibit academ market share survey
note survey conduct april pharma lab survey
note survey conduct april lab survey lc neglig
page
anticip pharma market share chang previou month vs next month data anticip academ market share chang previou month vs next month data yieldfcf compound-annual-growth-rate price-to-earnings rel tool median median median
pki new diagnost line chang stori
detail vanadi program uniqu legaci posit reproduct test given compani
screen newborn per year perform prenat biochem screen posit put
front key nation lab key opinion leader space launch europ low-cost
vanadi altern dna-bas non-invas prenat test nipt alreadi
exhibit shift special toward life scienc
market publish data vanadi
technolog establish sensit
detect trisomi marker down
syndrom fals posit
similar sequenc base
technolog recent data present
medic meet suggest result
improv expect earli traction europ
nation system nipt uptak
limit due cost concern public
vanadi valid work summer
valu studi run rhode island later year
may support
euroimmun look sustain pki entri
autoimmune/allergi market via euroimmun
smaller us china/europ
compani also stood benefit pki
commerci scale abil facilit fda approv process growth remain share gain
us larg commerci lab drive autoimmun share rapidli part thank test menu expans
per quarter euroimmun assay known high qualiti oper high specif recent autom
effort address histor concern labor-intens natur product
exhibit new product acquisit drive growth
exhibit euroimmun impact revenu mix
page
 new busi contribut mn euroimmunvanadisgenet shift diagnosticsgenet labvanadiseuroimmunlaboratori servicesenvironment shift pkidiagnosticsmedicalimaginglif sciencesfoodenvironment- industri
exhibit net debt ebitda ratio
exhibit organ ebit margin model expand bp
note agil includ keysight bill fx ilab multiplicom dilut
pension chang bond yield includ charg
exhibit wolf estd acceler stack organ growth
note organ growth consensu estim consensu nomin growth
estim less wolf estim inorgan impact revenu fx sell
day
genet lab detail launch
genet lab array high complex
test kit diagnost paradox disord
case predominantli newborn broader
reproduct health cord blood bank
franchis support commerci lever
lab previous guid sale
lab appear us stretch
goal rel roughli sale
scienc macro excit
execut margin target
critic forecast fastest organ
margin expans profil coverag group
note compani consist deliv
above-group organ increment margin
recent year commit
margin target anticip euroimmun
synergi mix shift higher margin
diagnost channel target impli
bp improv per year new cfo jami
mock team indic see upsid
trend give us reason doubt
give credit credit due estim
access bp increment organ
growth via known initi take diagnost
mix higher take mix diagnost
near sale roughli sale
year ago taken seri step
autoimmune/allergi franchis
sale launch low-cost substitut
sequencing-bas prenat diagnost
vanadi market launch
send-out genet lab led industri luminari
madhuri hegd play
market see path increment
sale lab vanadi
detail initi manag
articul expect growth
acceler bp top msd
page
note differ organ revenu growth wolf weight
averag tool coverag
exhibit newborn screen gain coverag global
exhibit pharma/academ mix recur revenu
exhibit vanadi euroimmun acquisit significantli
page
organ growth vs organ growthyoy vanadi screen revenu test offer newborn mix recur revenuesacademicpharma
page
total pharma salescro/cdmo salesr mfg small mol qa/qcsoftware/ servicessmal mol biotech/ larg wgtd
exhibit model organ increment growth expand
input less wolf estim inorgan margin growth adjust
exhibit organ ebit margin model expand
bp next year
note top bar repres report margin expans given year
acquisit activ
exhibit growth per share expect rebound
note agil includ keysight bill fx ilab multiplicom
dilut pension chang bond yield includ charg
note growth per share compound-annual-growth-rate taken base year better control
model rebound
page
organ increment vs consensuswr ebit margin expansionorg margin average organ ebit margin exp bpsorganicm impactoth averag exp organ average revenu instrumentsinstru intens vs convers alloc discontinu non-cash tax work alloc growth per share average
page
page
yieldfcf compound-annual-growth-rate ebitda compound-annual-growth-rate ev-ebitda vs estimate ebitda compound-annual-growth-rate tool ntm price-to-earnings ratio median price-to-earnings premium compound-annual-growth-rate
page
categori
note figur million unless state per-shar term
page
note figur million unless state per-shar term
page
report
note figur million unless state per-shar term
page
note figur million unless state per-shar term
page
op asset sale continu op debt issuanc cost acq inventori revalu assets/li total cont op dc op oper continu op dc op issuanc conting comp grant tax benefit grant proce cont op dc op financ fx net cash equival begin per per share share
